Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Boston Scientific Corp.
Mid-year update provided by drug-eluting stent maker
July 30th, 2003
Boston Scientific Corporation (BSX) announced preliminary, unaudited financial results for the second quarter, as well as estimates for net sales and earnings per share for the third quarter, the fourth quarter, and the year. The company also reported on the international introduction of its Taxus Express2 paclitaxel-eluting coronary stent system and the measures it is taking to support a successful U.S. launch. Preliminary net sales for the second quarter were $852 million, as compared to $708 million for the second quarter of 2002, an increase of 20%. Excluding the favorable impact of foreign currency fluctuations, net sales were $813 million, an...
Source: Biotech Week (2003-07-30)
|
